HEALTH● LOW2h ago · Oct 2, 2026, 9:27 PM
FDA extends review for Novo Nordisk's denecimig for hemophilia A
Seeking Alpha Tech · north america
The FDA has extended its review period for Novo Nordisk's drug, denecimig, which is intended for hemophilia A treatment. This indicates a delay in the regulatory approval process for the medication.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH2h agoThe FDA says cyclospora was found on a Mexican farm linked to a lettuce outbreakClarínHEALTH3h agoPatient died by suicide after insurance delayed medication: reportThe Independent WorldHEALTH3h agoEli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphomaSeeking Alpha TechHEALTH4h agoBiogen phase 2 litifilimab data boosts lupus candidateSeeking Alpha Tech